Guardant Health, Inc. $GH Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. lessened its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 59.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,847 shares of the company’s stock after selling 23,466 shares during the quarter. D.A. Davidson & CO.’s holdings in Guardant Health were worth $990,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC purchased a new stake in shares of Guardant Health during the 3rd quarter valued at about $39,523,000. Calamos Advisors LLC acquired a new stake in Guardant Health in the third quarter valued at approximately $2,780,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Guardant Health during the third quarter valued at approximately $675,000. Simplify Asset Management Inc. lifted its position in shares of Guardant Health by 16.8% during the third quarter. Simplify Asset Management Inc. now owns 31,100 shares of the company’s stock worth $1,943,000 after purchasing an additional 4,469 shares in the last quarter. Finally, Capricorn Fund Managers Ltd purchased a new position in shares of Guardant Health in the third quarter valued at $2,262,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on GH. Stifel Nicolaus lifted their price target on shares of Guardant Health from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday. UBS Group boosted their target price on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Wednesday. BTIG Research boosted their price objective on Guardant Health from $100.00 to $140.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, JPMorgan Chase & Co. increased their target price on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Twenty-two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.81.

Guardant Health Stock Up 1.3%

Shares of GH stock opened at $110.17 on Monday. The company has a market cap of $13.89 billion, a P/E ratio of -34.32 and a beta of 1.58. The business has a 50 day moving average of $102.14 and a two-hundred day moving average of $73.48. Guardant Health, Inc. has a 52 week low of $34.80 and a 52 week high of $113.91.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) earnings per share. Analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Transactions at Guardant Health

In other Guardant Health news, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $104.04, for a total transaction of $567,122.04. Following the completion of the transaction, the chief technology officer directly owned 7,012 shares of the company’s stock, valued at $729,528.48. The trade was a 43.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Terilyn J. Monroe sold 10,031 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $112.08, for a total transaction of $1,124,274.48. Following the completion of the sale, the insider owned 20,990 shares in the company, valued at $2,352,559.20. The trade was a 32.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 436,694 shares of company stock worth $45,632,343 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.